One-year @entity165 lowering treatment reduces medial temporal lobe XXXX and memory decline in @entity64 -free elderly with @entity955 : evidence from a parallel group randomized trial.

@entity1 @entity64 @entity73 @entity2993 @entity3709 @entity194 @entity955 @entity62 @entity165
OBJECTIVES: In elderly @entity1 with @entity955 ( @entity955 ), medial temporal lobe (MTL) @entity194 and @entity62 ( @entity62 ) may account for the @entity73 . Though a combination therapy of statins with @entity165 lowering agents like @entity3709 may be beneficial in @entity1 with @entity955 , its effects on MTL structure and @entity62 remains unknown. METHODS: A parallel group double-blinded randomized trial was performed during 1 year whereby elderly @entity64 -free @entity955 @entity1 either received placebo or @entity2993 and @entity3709 on top oral anticoagulation therapy. Neuropsychological performance and inflammatory markers in the blood were assessed at baseline and 1 year later together with amygdala and hippocampal volume as well as @entity62 . RESULTS: Sixty-three @entity1 were assessed for eligibility, but 29 @entity1 had to be excluded so that 34 @entity1 were randomized to both groups. In the treatment group, the systemic level of inflammation was significantly decreased after 1 year and an improvement in cognitive speed as well as short- and long-term memory was observed. While there was no significant difference in MTL volume at baseline, the placebo group exhibited more @entity194 for right amygdala and left hippocampus at follow-up. Finally, descriptive data showed a slight decline of @entity62 volume in the treatment group. CONCLUSIONS: In spite of limitations due to small sample size, our data suggest that intensive @entity165 lowering therapy in @entity955 @entity1 may slow @entity73 and @entity194 of the MTL. Though these results have to be replicated in a larger sample, they offer potential for future interventions.
